These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 34801695)

  • 1. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
    Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J
    Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
    Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
    Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.
    Khan M; Du K; Ai M; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Yuan Y; Tian Y
    Front Immunol; 2023; 14():1060308. PubMed ID: 36949944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
    Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J
    BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Yang H; Jin F; Zheng A
    Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
    Dent R; André F; Gonçalves A; Martin M; Schmid P; Schütz F; Kümmel S; Swain SM; Bilici A; Loirat D; Villalobos Valencia R; Im SA; Park YH; De Laurentis M; Colleoni M; Guarneri V; Bianchini G; Li H; Kirchmayer Machackova Z; Mouta J; Deurloo R; Gan X; Fan M; Mani A; Swat A; Cortés J
    Ann Oncol; 2024 Jul; 35(7):630-642. PubMed ID: 38755096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Atezolizumab Monotherapy or Combined Therapy with Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Alimohammadi M; Faramarzi F; Mafi A; Mousavi T; Rahimi A; Mirzaei H; Asemi Z
    Curr Pharm Des; 2023; 29(31):2461-2476. PubMed ID: 37921135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.
    Hattori M; Masuda N; Takano T; Tsugawa K; Inoue K; Matsumoto K; Ishikawa T; Itoh M; Yasojima H; Tanabe Y; Yamamoto K; Suzuki M; Pan W; Cortes J; Iwata H
    Cancer Med; 2023 May; 12(9):10280-10293. PubMed ID: 36916728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis.
    Villacampa G; Tolosa P; Salvador F; Sánchez-Bayona R; Villanueva L; Dienstmann R; Ciruelos E; Pascual T
    Cancer Treat Rev; 2022 Mar; 104():102352. PubMed ID: 35144055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Cui W; Luo Q; Sun SL; Xu JL; Gu H
    Recenti Prog Med; 2022 Dec; 113(12):722-732. PubMed ID: 36420848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis.
    Bianco N; Milano M; Pagan E; Oriecuia C; Bagnardi V; Rocco EG; Santomauro GI; Peruzzotti G; Colleoni M; Viale G
    Breast Cancer Res Treat; 2022 Jan; 191(1):137-145. PubMed ID: 34609640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
    Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
    Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
    Lehmann BD; Abramson VG; Dees EC; Shah PD; Ballinger TJ; Isaacs C; Santa-Maria CA; An H; Gonzalez-Ericsson PI; Sanders ME; Newsom KC; Abramson RG; Sheng Q; Hsu CY; Shyr Y; Wolff AC; Pietenpol JA
    JAMA Oncol; 2024 Feb; 10(2):193-201. PubMed ID: 38095878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
    Tarantino P; Gandini S; Trapani D; Criscitiello C; Curigliano G
    Crit Rev Oncol Hematol; 2021 Mar; 159():103223. PubMed ID: 33482345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow.
    Li Y; Liang X; Li H; Chen X
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.